Match!
Aurelia Haller
Takeda Pharmaceutical Company
VirologyVirusHuman metapneumovirusHuman Parainfluenza VirusBiology
32Publications
12H-index
912Citations
What is this?
Publications 10
Newest
#2Alex FranzusoffH-Index: 19
Last. Victoria Kelley HodsonH-Index: 1
view all 6 authors...
L'invention concerne des vaccins pouvant etre specialement formules pour obtenir une reponse immunitaire voulue. De preferences, certaines compositions de l'invention sont utilisees pour declencher une reponse immunitaire humorale, tandis que d'autres compositions sont utiles pour declencher de preference une reponse mediee par des cellules. L'invention concerne des combinaisons de compositions de vaccins utiles pour declencher ces deux types de reponse et/ou pour moduler le type de reponse immu...
#1Aurelia HallerH-Index: 12
#2Georg M. Lauer (Harvard University)H-Index: 44
Last. Richard C. Duke (University of Colorado Denver)H-Index: 32
view all 11 authors...
Control of primary infection with hepatitis C virus (HCV) is associated with robust and broad T cell immunity. In contrast, chronic infection is characterized by weak T cell responses suggesting that an approach that boosts these responses could be a therapeutic advance. Saccharomyces cerevisiae is an effective inducer of innate and adaptive cellular immunity and we have generated recombinant yeast cells (GI-5005) that produce an HCV NS3-Core fusion protein. Pre-clinical studies in mice showed t...
90 CitationsSource
#1Roderick Tang (MedImmune)H-Index: 19
#2Kutubuddin Mahmood (MedImmune)H-Index: 13
Last. Richard R. Spaete (MedImmune)H-Index: 20
view all 13 authors...
Abstract Human metapneumovirus (hMPV) infection causes respiratory tract disease similar to that observed during human respiratory syncytial virus infection (hRSV). hMPV infections have been reported across the entire age spectrum although the most severe disease occurs in young children. No vaccines, chemotherapeutics or antibodies are presently available for preventing or treating hMPV infections. In this study, a bovine/human chimeric parainfluenza virus type 3 (b/h PIV3) expressing the human...
69 CitationsSource
#1Sander HerfstH-Index: 33
#2Miranda de GraafH-Index: 27
Last. Ron A. M. FouchierH-Index: 92
view all 11 authors...
Human metapneumovirus (hMPV) is a newly discovered pathogen associated with respiratory tract illness, primarily in young children, immunocompromised individuals, and the elderly. The genomic sequence of the prototype hMPV isolate NL/1/00 without the terminal leader and trailer sequences has been reported previously. Here we describe the leader and trailer sequences of two hMPV isolates, NL/1/00 and NL/1/99, representing the two main genetic lineages of hMPV. Minigenome constructs in which the g...
88 CitationsSource
#1Mia MacPhail (MedImmune)H-Index: 11
#2Jeanne H. Schickli (MedImmune)H-Index: 13
Last. Aurelia Haller (MedImmune)H-Index: 12
view all 9 authors...
Human metapneumovirus (hMPV), a recently identified paramyxovirus, is the causative agent of respiratory tract disease in young children. Epidemiological studies have established the presence of hMPV in retrospective as well as current clinical samples in Europe, USA, Canada, Hong Kong and Australia. The hMPV disease incidence rate varied from 7 to 12%. This rate of disease attack places hMPV in severity between respiratory syncytial virus and human parainfluenza virus type 3, two common respira...
83 CitationsSource
#1Sridhar Pennathur (MedImmune)H-Index: 1
#2Aurelia Haller (MedImmune)H-Index: 12
Last. Kathleen L. Coelingh (MedImmune)H-Index: 15
view all 14 authors...
Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chim...
20 CitationsSource
#1Roderick TangH-Index: 19
#2Jeanne H. SchickliH-Index: 13
Last. Aurelia HallerH-Index: 12
view all 10 authors...
A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion (F) and hemagglutinin-neuraminidase (HN) genes of human PIV3, was used as a virus vector to express surface glycoproteins derived from two human pathogens, human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). RSV and hMPV are both paramyxoviruses that cause respiratory disease in young children, the elderly, and immunocompromised individuals. RSV has been known for decades to cause acute lower respira...
86 CitationsSource
#1Aurelia Haller (MedImmune)H-Index: 12
#2Misrach Mitiku (MedImmune)H-Index: 3
Last. Mia MacPhail (MedImmune)H-Index: 11
view all 3 authors...
Parainfluenza virus type 3 (PIV3) and respiratory syncytial virus (RSV) are the main causes of ubiquitous acute respiratory diseases of infancy and early childhood, causing 20–25 % of pneumonia and 45–50 % of bronchiolitis in hospitalized children. The primary goal of this study was to create an effective and safe RSV vaccine based on utilizing attenuated bovine PIV3 (bPIV3) as a virus vector backbone. bPIV3 had been evaluated in human clinical trials and was shown to be attenuated and immunogen...
19 CitationsSource
#1Aurelia HallerH-Index: 12
#1Aurelia HallerH-Index: 12
#2Tessa MillerH-Index: 1
Last. Kathleen L. CoelinghH-Index: 15
view all 4 authors...
Bovine parainfluenza virus type 3 (bPIV3) is being evaluated as an intranasal vaccine for protection against human PIV3 (hPIV3). In young infants, the bPIV3 vaccine appears to be infectious, attenuated, immunogenic, and genetically stable, which are desirable characteristics for an RNA virus vector. To test the potential of the bPIV3 vaccine strain as a vector, an infectious DNA clone of bPIV3 was assembled and recombinant bPIV3 (r-bPIV3) was rescued. r-bPIV3 displayed a temperature-sensitive ph...
61 CitationsSource
1